Lan He

Lan He

Auto-generated profile, based on publicly available information

Lan He

Memorial Sloan Kettering Cancer Center 1 Cancer Biology and Genetics Program, Sloan Kettering Institute New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
KKKangsan Kim
Kangsan Kim
HHHuocong Huang
Huocong Huang
PPPravat Kumar Parida
Pravat Kumar Parida
LHLan He
Lan He
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
SMSrinivas Malladi
Srinivas Malladi
Cell competition, a fitness-sensing process, is essential for tissue homeostasis. Using cancer metastatic latency models, we show that cell competition results in the displacement of latent metastatic (Lat-M) cells from the primary tumor. Lat-M cells resist anoikis and survive as residual metastatic disease. A memodeled extracellular matrix facilitates Lat-M cell displacement and survival in circulation. Disrupting cell competition dynamics by depleting secreted protein and rich in cysteine (SPARC) reduced displacement from orthotopic tumors and attenuated metastases. In contrast, depletion of SPARC after extravasation in lung-resident Lat-M cells increased metastatic outgrowth. Furthermore, multiregional transcriptomic analyses of matched primary tumors and metachronous metastases from patients with kidney cancer identified tumor subclones with Lat-M traits. Kidney cancer enriched for these Lat-M traits had a rapid onset of metachronous metastases and significantly reduced disease-free survival. Thus, an unexpected consequence of cell competition is the displacement of cells with Lat-M potential, thereby shaping metastatic latency and relapse. Significance: We demonstrate that cell competition within the primary tumor results in the displacement of Lat-M cells. We further show the impact of altering cell competition dynamics on metastatic incidence that may guide strategies to limit metastatic recurrences. This article is highlighted in the In This Issue feature, p. 1

8 January 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
JPJin Suk Park
Jin Suk Park
CKCarson Kenum
Carson Kenum
LHLan He
Lan He
AKAbdul G. Khan
Abdul G. Khan
MPMary Ann Pohl
Mary Ann Pohl
KGKaruna Ganesh
Karuna Ganesh
Effective treatment for metastatic cancer has remained elusive because of the persistence of drug-resistant metastasis stem cells (MetSC) that drive relapse. MetSCs are tumor cell subpopulations enriched for their ability to reinitiate and sustain metastatic growth, displaying phenotypic plasticity and resistance to chemotherapy. These cells express the L1 cell adhesion molecule (L1CAM), a transmembrane protein detected in numerous human solid tumor types and at multiple disseminated organ sites. As a selective surface marker of MetSCs, L1CAM is a promising candidate for molecularly targeted drugs aimed at eliminating metastases, yet strategies to date have not achieved clinical success. In this study, we develop antibody–drug conjugates (ADC) to deliver highly toxic PNU-159682 payloads to L1CAM-expressing cells. We report the generation of monoclonal antibodies (mAb) with high binding affinity, specificity, and selectivity for the human L1CAM extracellular domain. Optimized L1CAM-targeting mAbs were conjugated to PNU-159682 to generate ADC variants with both cleavable and noncleavable linkers, with an average drug–antibody ratio of four. ADCs derived from three antibodies targeting various epitopes of the L1CAM extracellular portion potently killed cells exhibiting varying levels of surface L1CAM expression. L1CAM ADCs given as monotherapy resulted in robust tumor control and extended survival in mice harboring subcutaneous L1CAM+ xenografts or L1CAM+ lung metastases from triple-negative basal breast cancer and lung adenocarcinoma. Safety analyses with mouse cross-reactive antibodies indicate a feasible therapeutic window. Our findings offer strong proof of concept to support the preclinical development of these novel L1CAM ADCs as therapeutic agents for advanced solid tumors.

10 December 2025
Verified
Other
Open access
KKKangsan Kim
Kangsan Kim
HHHuocong Huang
Huocong Huang
PPPravat Kumar Parida
Pravat Kumar Parida
LHLan He
Lan He
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
SMSrinivas Malladi
Srinivas Malladi
Video shows displacement of Lat-M cells in cell competition. Lat-M cells (Green) surrounded by PA (Red) cells being displaced under cell competition assay conditions.

10 December 2025
Verified
Other
Open access
KKKangsan Kim
Kangsan Kim
HHHuocong Huang
Huocong Huang
PPPravat Kumar Parida
Pravat Kumar Parida
LHLan He
Lan He
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
SMSrinivas Malladi
Srinivas Malladi
Video shows displacement of Lat-M cells in cell competition. Lat-M cells (Green) surrounded by PA (Red) cells being displaced under cell competition assay conditions.

4 April 2023
Verified
Other
Open access
KKKangsan Kim
Kangsan Kim
HHHuocong Huang
Huocong Huang
PPPravat Kumar Parida
Pravat Kumar Parida
LHLan He
Lan He
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
SMSrinivas Malladi
Srinivas Malladi
Video shows displacement of Lat-M cells in cell competition. Lat-M cells (Green) surrounded by PA (Red) cells being displaced under cell competition assay conditions.

4 April 2023
Verified
Other
Open access
KKKangsan Kim
Kangsan Kim
HHHuocong Huang
Huocong Huang
PPPravat Kumar Parida
Pravat Kumar Parida
LHLan He
Lan He
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
SMSrinivas Malladi
Srinivas Malladi
Video shows displacement of Lat-M cells in cell competition. Lat-M cells (Green) surrounded by PA (Red) cells being displaced under cell competition assay conditions.